RxSight, Inc. RXST

Company Overview

RxSight, Inc. is a commercial-stage medical technology company focused on improving outcomes in cataract surgery through adjustable intraocular lens technology. The company operates within the ophthalmology and medical devices industries, specifically addressing refractive accuracy challenges following cataract procedures. Its core innovation is a system that allows physicians to non-invasively adjust a patient’s implanted lens after surgery to optimize visual acuity.

RxSight’s primary revenue drivers are its proprietary Light Adjustable Lens (LAL) and the associated Light Delivery Device (LDD), which together form an integrated platform. The company serves ophthalmic surgeons, ambulatory surgery centers, and ophthalmology practices, primarily in developed healthcare markets. Its unique positioning lies in being the first and only company to commercialize an FDA-approved adjustable intraocular lens, offering a differentiated solution compared to traditional fixed-power lenses.

The company was founded in 1997 and spent more than two decades in research, clinical development, and regulatory approval processes before achieving U.S. Food and Drug Administration approval for its core technology. RxSight transitioned to a commercial-stage company following FDA approval and completed its initial public offering in 2021, marking its evolution from a development-focused enterprise to a revenue-generating medical device manufacturer.